Disc Medicine (IRON) Q3 2026 earnings review
Disc Medicine's lead drug passes its trial, and cash grows
Disc Medicine, a developer of drugs for rare blood diseases, cleared its biggest clinical hurdle and raised enough cash to fund operations into 2030. Its lead drug bitopertin succeeded in a late-stage trial by cutting a toxic blood buildup by 41% and giving patients 12 extra hours of pain-free sunlight a month. Chief executive John Quisel followed the win with an October share sale that brought the total cash pile to about $1.17 billion by our math.
| Operating costs, excluding last year's $10M milestone | +11% from a year ago by our math (reported: -5%) |
|---|---|
| Bitopertin Phase 3 pain-free sunlight gain | +12.2 hours per month vs placebo in month 6 (p=0.0010) |
| Cash and securities, including October offering | $1.17B by our math ($683M at Q3 end + $486M net proceeds) |
| Cash runway outlook | Extended to 2030 prior plan: into 2029 |
⚖️ Verdict: 🟢 Bullish
The story got much better because the trial answered the exact question that caused US regulators to reject bitopertin in February 2026. Back then, the agency wanted proof that lower blood toxin levels actually translate into pain-free time outdoors, and this trial delivered both. Two cautions remain: half of the patients on the drug felt dizzy, and underlying operating costs rose 11% from a year ago by our math once a one-time payment is stripped out.
The question now is whether regulators will approve bitopertin with a clean label by the middle of 2027 and agree on late-stage trial designs for the next two blood drugs. A smooth approval and clear trial rules would let the company launch its first medicine while running two more major studies, whereas new regulatory delays would eat into the cash pile. Year-end feedback from the agency on the myelofibrosis drug and the formal bitopertin filing will settle the first step.
🐂 Bull Case
Bitopertin Passed the Sunlight Test the FDA Demanded
Disc Medicine is developing bitopertin, an oral drug for erythropoietic protoporphyria (EPP), a rare genetic disease that causes painful skin reactions in sunlight. In February 2026, US regulators rejected the company's application for early approval because they wanted stronger proof that lowering a blood toxin called PPIX actually lets patients spend more time outdoors.
"In our first pivotal trial readout as a company, APOLLO delivered strong and compelling evidence of the potential clinical benefit of bitopertin for patients with EPP," chief executive John Quisel said. The late-stage APOLLO trial tested that exact link and met every primary and secondary goal.
- Blood toxin reduction: bitopertin "reduced whole-blood metal-free PPIX by 41.4% versus placebo"
- Sunlight tolerance: patients gained 12.2 hours of pain-free light exposure per month in month six over placebo
- Target US population: about 6,000 diagnosed patients out of 14,000 addressable patients aged 12 and older
This result matters because it directly answers the regulator's objection from February. Quisel plans to resubmit the drug application by the end of 2026, which puts a potential approval decision in the middle of 2027.
What to watch: the formal acceptance of the resubmitted application by US regulators in early 2027. Acceptance will confirm that the agency agrees the trial data are complete and sets the official review clock for mid-2027.
October Share Sale Extends Cash Into 2030
As a clinical-stage drug developer with no product sales, Disc Medicine relies on its cash balance to pay for trials and prepare for its first commercial launch. The company ended September with $682.8 million in cash and marketable securities, down $34.9 million from June by our math.
Right after the quarter closed in October 2026, the biotechnology group sold new shares in a public offering and raised $485.9 million in net proceeds. By our math, that brings its combined cash pile to roughly $1.17 billion.
Management said the new money extends its funding into 2030, one year longer than its previous 2029 plan. Quisel said the balance sheet can now "support the anticipated launch of bitopertin and advance two additional programs toward pivotal-stage development in 2027" without needing more cash before the first drug goes on sale.
What to watch: quarterly cash burn in the fourth quarter of 2026 as two more drugs prepare for late-stage trials. A sharp rise in quarterly spending would test how comfortably the cash pile lasts into 2030.
Two Blood-Disorder Drugs Move Toward Late-Stage Trials
Beyond bitopertin, Disc Medicine is testing two antibody drugs that control iron levels in the blood. DISC-3405 treats polycythemia vera (PV), a disease in which the bone marrow makes too many red blood cells, and selcodebart treats severe anemia in patients with myelofibrosis (MF), a bone marrow cancer.
During the quarter, the company shared initial mid-stage data for DISC-3405 dosed every two weeks. Quisel said the results "reinforce the potential of DISC-3405 to maintain target hematocrit levels and improve symptoms for patients with polycythemia vera". Both drugs target larger US patient groups than bitopertin, with 75,000 treated PV patients and 22,000 addressable MF anemia patients.
What to watch: December 2026 presentations at the American Society of Hematology meeting and feedback from the year-end FDA meeting on selcodebart. Those updates will show whether DISC-3405 works when dosed once every four weeks and will lock in the late-stage trial design for selcodebart.
🐻 Bear Case
Half of Bitopertin Patients Reported Dizziness
Even when a drug meets its main goals in a clinical trial, side effects can shape its warning label and how readily doctors prescribe it. In the APOLLO trial, bitopertin showed a noticeable rate of nervous-system side effects.
Disc Medicine reported that half of the patients taking bitopertin experienced dizziness, making it the most common side effect in the study. The drug developer noted that the dizziness was "mild or moderate and generally transient" and that no side effects exceeded Grade 3 severity.
Still, a 50% rate in a chronic daily pill for adults and teenagers aged 12 and up is high. If patients stop taking the pill in the real world when they feel dizzy, commercial use could fall short of the 6,000 diagnosed US patients.
What to watch: the full APOLLO trial discontinuation rates and dose-reduction numbers when detailed medical data are presented. High dropout rates from dizziness would point to slower real-world adoption after launch.
Hiring Keeps Raising Underlying Costs Before First Sales
Disc Medicine reported a smaller third-quarter net loss of $59.5 million, down from $62.3 million a year ago, as reported research and development spending fell 12.4% to $44.1 million. That drop makes spending look cooler than it really is.
Last year's third quarter included a one-time $10.0 million milestone payment for starting the DISC-3405 mid-stage study. Stripping out that $10.0 million payment, underlying research spending rose 9.3% from a year ago and total operating costs climbed 11.2% by our math, driven by "higher personnel-related costs driven by increased headcount".
- Underlying research and development: up 9.3% from a year ago by our math, versus a 12.4% reported drop
- Selling, general and administrative costs: $20.1 million, up 15.7% from a year ago and 10.7% from last quarter
- Nine-month operating expenses: $198.8 million, up 17.6% from a year ago
Overhead and commercial preparation now take up 31.3% of total operating spending, up from 25.6% a year ago by our math. Because the February regulatory rejection pushed a potential bitopertin decision to mid-2027, the company is carrying a growing sales and administrative payroll for an extra year without product revenue.
What to watch: selling, general and administrative spending in the fourth quarter of 2026. Another double-digit quarterly jump would show commercial overhead expanding months before regulators decide on bitopertin.
💲 Other KPIs
Share count rose 10.6% from a year ago, up from 35.2 million shares in the third quarter of 2025. The increase came from two equity offerings in 2025 and lowered the net loss per share by 13.6% even though total net loss fell only 4.5%. The October 2026 share sale will raise the count further in Q4.
Long-term liabilities doubled from $30.4 million at the end of 2025 to $60.9 million at the end of September, after stepping up to $60.5 million in the second quarter. Management mentions debt service obligations in its cash outlook, so the higher balance adds fixed financing costs alongside trial spending.
🔮 Guidance
Raised. Management extended its cash outlook by one year into 2030 after raising $485.9 million in October 2026. The company had held the 2029 target for four straight quarters. By our math, the combined $1.17 billion cash balance leaves room for roughly $250 million to $300 million in yearly cash burn over the next three and a half years.
Unchanged. The biotechnology group still expects a regulatory decision on bitopertin by the middle of 2027, and now specifies that the application will go back to the agency by the end of 2026. That timeline implies a six-month regulatory review during the first half of 2027.
Unchanged. Disc Medicine will announce regulatory feedback from its meeting with the FDA and lay out its late-stage trial plans for selcodebart in myelofibrosis anemia before the year ends. Updated mid-stage trial data will also arrive in December at the hematology conference.
Unchanged. The drugmaker narrowed its fourth-quarter window to the December 2026 hematology meeting. It will present initial results for patients dosed every four weeks in the mid-stage polycythemia vera study and first data from the early-stage sickle cell disease trial.
❓ Key Questions
How many APOLLO patients stopped taking bitopertin due to dizziness?
Half of the patients in the bitopertin arm reported dizziness. Investors need the exact dropout and dose-reduction rates to judge how well patients will stay on the daily pill once it is sold commercially.
How many shares did Disc Medicine issue in October?
The press release states that the October 2026 public offering brought in $485.9 million in net proceeds, but it does not give the number of new shares or pre-funded warrants issued.
What will the two new late-stage trials cost in 2027?
Management plans to move both selcodebart and DISC-3405 toward late-stage trials in 2027 while launching bitopertin. Management has not said how much quarterly research spending will rise when both studies start enrolling.
Does the Commissioner's Priority Voucher still shorten the bitopertin review?
Disc Medicine received a national priority voucher in 2025 meant to cut FDA review to one or two months, yet its timeline sets a six-month gap between year-end resubmission and a mid-2027 decision.